FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT	OF CHANG	ES IN BENEF	ICIAL OWNE	RSHIP

OMB APPRO	DVAL			
OMB Number:	3235-0287			
Estimated average burd	en			
hours per response:	0.5			

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* TARNOW MICHAEL M				2. Issuer Name and Ticker or Trading Symbol Xenon Pharmaceuticals Inc. [XENE]									Relationship heck all appli X Directo	,					
(Last) (First) (Middle) C/O XENON PHARMACEUTICALS INC 200 - 3650 GILMORE WAY					Date of Earliest Transaction (Month/Day/Year) 06/02/2016 4. If Amendment, Date of Original Filed (Month/Day/Year)								6.	Officer (give title below) Other (specify below) 6. Individual or Joint/Group Filing (Check Applicable					
(Street) BURNABY A1 V5G 4W8			The state of the s							Li	Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person								
(City) (State) (Zip)																			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				ction 2A. Deemed Execution Date,			3. Transact Code (In: 8)	(Instr. 5) (A) or D			ed (A) or str. 3, 4 ar	5. Amou Securiti Benefici Owned Reporte Transac	unt of es 6. O Form ially (D) of Following ed etion(s)		: Direct c r Indirect E str. 4)	. Nature of Indirect Beneficial Ownership Instr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate, Ti	ransac ode (In	5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)		
				С	ode \	v	(A)	(D)	Date Exercisable	Exp Dat	oiration te	Title	Amount or Number of Shares	1					
Stock Option (Right to Buy)	\$7.38	06/02/2016			A		3,500		(1)	06/0	01/2026	Common Shares	3,500	\$0.00	3,500		D		
Stock Option (Right to Buy)	\$7.38	06/02/2016			A		1,250		(2)	06/0	01/2026	Common Shares	1,250	\$0.00	1,250		D		

Explanation of Responses:

- 1. One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, and the balance of the total shares subject to the Option shall vest on the three year anniversary of the grant date.
- 2. Options shall vest 100% on the one year anniversary of the grant date.

/s/ Joanne Smartt, Attorney-infact

** Signature of Reporting Person

06/03/2016

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

The undersigned, as a Section 16 reporting person of Xenon Pharmaceuticals Inc. (the "Company"), hereby constitutes and appoints each of the responsible attorneys and paralegals of Wilson Sonsini Goodrich & Rosati, Professional Corporation, and each of Emmanuelle Vallee, Sherry Aulin, Joanne Smartt and Huda Shami of the Company, the undersigned's true and lawful attorney-in-fact to:

- 1. complete and execute Forms ID, 3,4 and 5 and other forms and all amendments thereto as such attorney-in-fact shall in his or her discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company; and
- 2. do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national association, the Company and such other person or agency as the attorney-in-fact shall deem appropriate.

The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 (as amended).

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms ID, 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 3rd day of December, 2015.

Signature: /s/ Michael Tarnow

Michael Tarnow